Amphetamine and mCPP Effects on dopamine and serotonin striatal in vivo microdialysates in an animal model of hyperactivity

Neurotoxicity Research

Volumn 11, Issue 2, 2007, Pages 131-144

  Nowak, Przemyslaw ^a   Bortel, Aleksandra ^a   Dabrowska, Joanna ^a   Oswiecimska, Joanna ^a   Drosik, Marzena ^a   Kwiecinski, Adam ^a   Opara, Józef ^a   Kostrzewa, Richard M ^b   Brus, Ryszard ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b East Tennessee State University   (United States)

Author keywords

5,7 Dihydroxytryptamine; 6 Hydroxydopamine; ADHD; Amphetamine; Biogenic amines; Brain microdialysis; m Chlorophenylpiperazine

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 3,4 DIHYDROXYPHENYLACETIC ACID; DEXAMPHETAMINE; DOPAMINE; SEROTONIN; 1-(3-CHLOROPHENYL)PIPERAZINE; 5 HYDROXYINDOLEACETIC ACID; 5,6 DIHYDROXYTRYPTAMINE; ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; CENTRAL STIMULANT AGENT; OXIDOPAMINE; PIPERAZINE DERIVATIVE; SEROTONIN AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENUATION; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE LEVEL; DOPAMINE BRAIN LEVEL; DRUG MECHANISM; HYPERACTIVITY; LOCOMOTION; MALE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BRAIN LEVEL; AGE; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; FEMALE; METABOLISM; MICRODIALYSIS; PREGNANCY; WISTAR RAT;

ANIMALIA; RATTUS;

3,4-DIHYDROXYPHENYLACETIC ACID; 5,6-DIHYDROXYTRYPTAMINE; AGE FACTORS; AMPHETAMINE; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; HYDROXYINDOLEACETIC ACID; MALE; MICRODIALYSIS; OXIDOPAMINE; PIPERAZINES; PREGNANCY; RATS; RATS, WISTAR; SEROTONIN; SEROTONIN AGONISTS; SYMPATHOLYTICS;

EID: 34249691166     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033391     Document Type: Article

References (79)

1. 2C receptors. Synapse 55, 242-251.
2. Aspide R, UA Gioroni Carneval, JA Sergeant and AG Sadile (1998) Non-selective attention and nitric oxide in putative animal models of attention-deficit hyperactivity disorder. Behav. Brain Res. 95, 123-133.
3. 1A receptor agonist on striatal dopamine release. Synapse 57, 67-75.
4. Benloucif S, MJ Keegan and MP Galloway (1993) Serotonin-facilitated dopamine release in vivo: Pharmacological characterization. J. Pharmacol. Exp. Ther. 265, 373-377.
5. Berger TW, S Kaul, EM Stricker and MJ Zigmond (1985) Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res. 336, 354-358.
6. Biederman J and T Spencer (1999) Attention-deficit/hyperac-tivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry 46, 1234-1242.
7. Bjelke B, I Stromberg, WT O'Connor, B Andbjer, LF Agnati and K Fuxe (1994) Evidence for volume transmission in the dopamine denervated neostriatum of the rat after a unilateral nigral 6-OHDA microinjection. Studies with systemic D- amphetamine treatment. Brain Res. 662, 11-24.
8. 3H]5-hydroxytryptamine in the rat CNS. J. Neurochem. 46, 1392-1398.
9. Boschert U, DA Amara, L Segu and R Hen (1994) The mouse 5-hydroxytryptamine(1B) receptor is localized predominantly on axon terminals. Neuroscience 58, 167-182.
10. Boyce PJ and JM Finlay (2005) Neonatal depletion of cortical dopamine: effects on dopamine turnover and motor behavior in juvenile and adult rats. Brain Res. Dev. Brain Res. 156, 167-175.
11. Brus R, RM Kostrzewa, KW Perryand RW Fuller(1994) Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is eliminated by neonatal 5,7-dihydroxytryptamine treatment. J. Pharmacol. Exp. Ther. 268, 231-237.
12. Brus R, P Nowak, R Szkilnik, U Mikolajun and RM Kostrzewa (2004) Serotoninergic attenuate hyperlocomotor activity in rats. Potential new therapeutic strategy for hyperactivity. Neurotoxicity Res. 6, 317-326.
13. Butcher SP, IS Fairbrother, JS Kelly and GW Arbuthnott (1988) Amphetamine-induced dopamine release in the rat striatum: An in vivo microdialysis study. J. Neurochem. 50, 346-355.
14. Bymaster FP, JS Katner, DL Nelson, SK Hemrick-Luecke, PG Threlkeld, JH Heiligenstein, SM Morin, DR Gehlert and KW Perry (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/hyper-activity disorder. Neuropsychopharmacology 27, 699-711.
15. Castaneda R, N Sussman, R Levy and M Trujillo (1999) A treatment algorithm for attention deficit hyperactivity disorder in cocaine-dependent adults: A one-year private practice study with long-acting stimulants, fluoxetine, and bupro-pion. Subst. Abuse 20, 59-71.
16. 2C receptors. Trends Pharmacol. Sci. 22, 502-504.
17. DeDeurwaerdere P, S Navailles, KA Berg, WP Clarke and US pampinato (2004) Constitutive activity of the serotonin(2C) receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci. 24, 3235-3241.
18. Dell'Anna ME, J Luthman, E Lindqvist and L Olsen (1993) Development of monoamine systems after neonatal anoxia in rats. Brain Res. Bull. 32, 159-170.
19. Di Giovanni G, P De Deurwaerdere, M Di Mascio, V Di Matteo, E Esposito and U Spampinato (1999) Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: A combined in vivo electrophysiological and microdialysis study. Neuroscience 91, 587-597.
20. Di Giovanni G, V Di Matteo, M Di Mascio and E Esposito (2000) Preferential modulation of mesolimbic vs. nigrostriatal dopaminergic function by serotonin(2C/2B) receptor agonists: A combined in vivo electrophysiological and microdialysis study. Synapse 35, 53-61.
21. Elia J, BG Borcherding, JL Rapoport and CS Keysor (1991) Methylphenidate and dextroamphetamine treatments of hyperactivity: Are there true nonresponders? Psychiatry Res. 36, 141-155.
22. Eriksson E, G Engberg, O Bingand H Nissbrandt (1999) Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 20, 287-296.
23. Ernst M, LL Liebenauer, D Tebeka, PH Jons, G Eisenhofer, DL Murphyand AJ Zametkin (1997) Selegiline in ADHD adults: Plasma monoamines and monoamine metabolites. Neuropsychopharmacology 16, 276-284.
24. Faraone SV, RH Perlis, AE Doyle, JW Smoller, JJ Goralnick, MA Holmgrenand P Sklar (2005) Molecular genetics of attention-deficit/ hyperactivity disorder. Biol. Psychiatry 57, 1313-1323.
25. Galloway MP, CS Suchowski, MJ Keegan and S Hjorth (1993) Local infusion of the selective 5HT-1B agonist CP-93,129 facilitates striatal dopamine release in vivo. Synapse 15, 90-92.
26. Gobert A, JM Rivet, F Lejeune, A Newman-Tancredi, A Adhumeau-Auclair, JP Nicolas, L Cistarelli, C Melon and MJ Millan (2000) Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adren-ergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 36, 205-221.
27. Gong L and RM Kostrzewa (1992) Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats. Pharmacol. Biochem. Behav. 41, 621-623.
28. Gong L, RM Kostrzewa, RW Fuller and KW Perry (1992) Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J. Pharmacol. Exp. Ther. 261, 1000-1007.
29. Gonon F, F Navarre and M Buda (1984) In vivo monitoring of dopamine release in the rat brain with differential normal pulse voltammetry. Anal. Chem. 56, 573-575.
30. 1 receptor stimulation on striatal preprotachykinin mRNA expression in the 6-hydroxydopamine lesioned rat. Brain Res. Mol. Brain Res. 70, 125-134.
31. Heffner TG and LS Seiden (1982) Possible involvement of serotonergic neurons in the reduction of locomotor hyperactivity caused by amphetamine in neonatal rats depleted of brain dopamine. Brain Res. 244, 81-90.
32. Hendley ED, DJ Wessel and J Van Houtten (1986) Inbreeding of Wistar-Kyoto rat strain with hyperactivity but without hypertension. Behav. Neurol. Biol. 45, 1-16.
33. Herrera-Marschitz M, J Luthman and S Ferre (1994) Unilateral neonatal intracerebroventricular 6-hydroxydopamine administration in rats: II. Effects on extracellular monoamine, acetylcholine and adenosine levels monitored with in vivo microdialysis. Psychopharmacology (Berl.) 116, 451-456.
34. Hynd GW, KL Horn and RM Marshall (1991) Neurobiological basis of attention deficit hyperactivity disorder (ADHD). School Psychol. Rev. 20, 174-186.
35. B syn-aptic potential in rat dopamine neurons. J. Neurosci. 12, 2000-2006.
36. Jones SR, JD Joseph, LS Barak, MG Caron and RM Wightman (1999) Dopamine neuronal transport kinetics and effects of amphetamine. J. Neurochem. 73, 2406-2414.
37. Kankaanpaa A, E Meririnne, P Lillsunde and T Seppala(1998) The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens. Pharmacol. Biochem. Behav. 59, 1003-1009.
38. Kasperska A, R Brus, A Sokola, RM Kostrzewa and J Shani (1999) Sexual differentiation in the central dopaminergic effect of nitric oxide donors and inhibitor on stereotyped behavior changes induced by amphetamine, but not by apo-morphine. Pharmacol. Rev. Comm. 10, 329-339.
39. +-dependent mechanism. J. Biol. Chem. 278, 12070-12077.
40. Kirby LG, DS Kreiss, A Singhand I Lucki (1995) Effect of destruction of serotonin neurons on basal and fenfluramine-induced serotonin release in striatum. Synapse 20, 99-105.
41. 1 receptors mediate enhanced oral activity after neonatal 6-OHDA. Pharmacol. Biochem. Behav. 39, 677-682.
42. Kostrzewa RM, L Gongand R Brus (1993) Serotonin (5-HT) systems mediate dopamine (DA) receptor supersensitivity. Acta Neurobiol. Exp. (Wars.) 53, 31-41.
43. Kostrzewa RM, R Brus, JH Kalbfleish, KW Perry and RW Fuller (1994) Proposed animal model of attention deficit hyperactivity disorder. Brain Res. Bull. 34, 161-167.
44. Kostrzewa RM, TA Reader and L Descarries (1998) Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J. Neurochem. 70, 889-898.
45. Kostrzewa RM, P Nowak, JP Kostrzewa, RA Kostrzewa and R Brus (2005) Peculiarities of L-DOPA treatment of Parkinson's disease. Amino Acids 28, 157-164.
46. Lucki I, HR Ward and A Frazer (1989) Effect of 1-(m-chlorophenyl)piperazine and 9-(m-trifluoromethylphenyl) piperazine on locomotor activity. J. Pharmacol. Exp. Ther. 249, 155-164.
47. Lucot JB and LS Seiden (1982) Effects of neonatal administration of 5,7-dihydroxytryptamine on locomotor activity. Psychopharmacology (Berl.) 77, 114-116.
48. Luthman J, A Fredriksson, T Lewander, G Jonsson and T Archer (1989) Effects of d-amphetamine and methyl-pheni-date on hyperactivity produced by neonatal 6-hydroxydopa-mine treatment. Psychopharmacology (Berl.) 99, 550-557.
49. 2 receptors of exogenous L-DOPA-derived dopamine release in the dopaminergic denervated striatum. Brain Res. 817, 185-191.
50. Magara F, L Ricceri, DP Wolfer and HP Lipp (2000) The acallosal mouse strain I/LnJ: A putative model of ADHD? Neurosci. Biobehav. Rev. 24, 45-50.
51. 1B binding sites following 5,7-dihydroxytryptamine axotomy in the adult rat. Brain Res. 623, 345-348.
52. 1B serotonin receptor: Cloning, functional expression, and localization in motor control centers. Proc. Natl. Acad. Sci. USA 89, 3020-3024.
53. 2A sites for PCP-induced locomotion in the rat. Eur. J. Neurosci. 11, 4419-4432.
54. Miller FE, TG Heffner, C Kotake and LS Seiden (1981) Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to the extent of brain dopamine depletion. Brain Res. 229, 123-132.
55. Moran-Gates T, K Zhang, RJ Baldessarini and FI Tarazi (2005) Atomoxetine blocks motor hyperactivity in neonatal 6-hydroxydopamine-lesioned rats: implications for treatment of attention-deficit hyperactivity disorder. Int. J. Neuropsychopharmacol. 8, 439-444.
56. 2 receptors. J. Neurosci. Res. 55, 600-607.
57. Nowak P, RM Kostrzewa, A Kwiecinski, A Bortel, L Labus and R Brus (2005) Neurotoxic action of 6-hydroxydopamine on the nigrostriatal dopaminergic pathway in rats sensitized with D-amphetamine. J. Physiol. Pharmacol. 56, 325-333.
58. 2 antagonists. J. Neurochem. 60, 1792-1799.
59. Paxinos G and C Watson (1986) The Rat Brain in Stereotaxic Coordinates, 2nd Ed. (Academic Press:SYdney).
60. Puumala T, S Ruotsalainen, P Jakala, E Koivisto, P Riekkinen Jr and J Sirvio (1997) Behavioral and pharmacological studies on the validation of a new animal model for attention deficit hyperactivity disorder. Neurobiol. Learn. Mem. 66, 198-211.
61. 1A receptor binding sites in the rat brain: A quantitative autoradiographic study. J. Neurochem. 58, 1338-1346.
62. 2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism. Exp. Neurol. 129, 57-63.
63. Russell VA, T Sagvolden and EB Johansen (2005) Animal models of attention-deficit hyperactivity disorder. Behav. Brain Funct. 1, 9.
64. Sagvolden T (2000) Behavioral validation of the spontaneously hypertensive rats (SHR) as an animal model of attention-deficit/ hyperactivity disorder (ADHD). Neurosci. Biobehav. Rev. 24, 31-39.
65. Sagvolden T, MA Metzger, HK Schiorbeck, AL Rugland, I Spinnaugr and G Sagvolden (1992) The spontaneously hypertensive rat (SHR) as an animal model of childhood hyperactivity (ADHD): Changed reactivity to reinforcers and to psychomotor stimulants. Behav. Neurol. Biol. 58, 103-112.
66. 3H]dopamine from rat striatal synaptosomes. Naunyn Schmiedebergs Arch. Pharmacol. 359, 40-47.
67. Shaywitz BA, JH Klopper and JW Gordon (1976a) Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine. Nature 261, 153-155.
68. Shaywitz BA, RD Yagerand JH Klopper (1976b) Selective brain dopamine depletion in developing rats: An experimental model of minimal brain dysfunction. Science 191, 305-308.
69. Silbergeld EK and AM Goldberg (1974) Lead-induced behavioral dysfunction: An animal model of hyperactivity. Exp. Neurol. 42, 146-157.
70. Snyder AM, MJ Zigmond and RD Lund (1986) Sprouting of serotonergic afferents into striatum after dopamine depleting lesions in infant rats: a retrograde transport and immunocy-tochemical study. J. Comp. Neurol. 245, 274-281.
71. Starr HL and J Kemner (2005) Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: Treatment outcomes in African-American children with ADHD. J. Natl. Med. Assoc. 97, 11S-16S.
72. Swanson JM, JA Sergeant, E Taylor, EJS Sonuga-Barke, PS Jansen and DP Canwell (1998) Attention deficit hyperactivity disorder and hyperkinetic disorder. Lancet 351, 429-433.
73. Tseng KY, L Kargieman, S Gacio, LA Riquelme and MG Murer (2005) Consequences of partial and severe dopami-nergic lesion on basal ganglia oscillatory activity and akine-sia. Eur. J. Neurosci. 22, 2579-2586.
74. Wagner J, P Vitali, MG Polfregman, M Zraika and S Hnot (1982) Simultaneous determination of 3,4-dihydroxyphenylalanine, 5-hydroxytryptophan, dopamine, 4-hydroxy-3-methoxyphe-nylalanine, norepinephrine, 3,4-dihydroxyphenylacetic acid, homovanillic acid, serotonin and 5-hydroxyindolacetic acid in rat cerebrospinal fluid and brain by high-performance liquid chromatography with electrochemical detection. J. Neurochem. 38, 1241-1254.
75. Weiss G (1985) Hyperactivity. Overview and new directions. Psychiatr. Clin. N. Am. 8, 737-753.
76. Westerink BH (1995) Brain microdialysis and its application for the study of animal behaviour. Behav. Brain Res. 70, 103-124.
77. Zetterström T, T Sharp, CA Marsden and U Ungerstedt (1983) In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J. Neurochem. 41, 1769-1773.
78. 4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopa-mine lesions. Psychopharmacology (Berl.) 161, 100-106.
79. 18F-MPPF binding in the rat hippocampus. J. Nucl. Med. 44, 1495-501.